Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials – PR Web

Asymmetrex discusses new advances for supply of traditional drug development and advanced therapy medicinal product (ATMP) clinical trials

BOSTON (PRWEB) October 01, 2020

Adapting to the present COVID crisis, this year the 2020 Outsourcing in Clinical Trials USA Conference, one of several international clinical trials supply trade conferences organized by Arena International Events Group each year, adopted a virtual meeting format. The conference, scheduled for September 30-October 1, continued its tradition of bringing together contract research organization suppliers and company sponsors in the clinical trials supply industry to discuss new developments and best practices.

Among the many industry members invited to speak in the event, James L. Sherley, M.D., Ph.D., founder and director of Massachusetts stem cell biotechnology company Asymmetrex, presented on September 30. Dr. Sherleys presentation highlighted a growing new area of the clinical trials supply industry. More and more, the clinical trials supply industry is considering better technology and practices to support stem cell clinical trials and gene therapy clinical trials that utilize advanced therapy medicinal products. In particular, Dr. Sherley discussed the value of implementing new quantification technologies for ATMPs developed with tissue stem cells. He answered the rhetorical question that was the title of his talk How can we outsource stem cell clinical trials without counting tissue stem cells? by detailing places in ATMP supply chains where instituting counting technologies would provide significant benefits to the stem-gene clinical trials supply industry and the patients it serves.

Sherley also presented innovation proposals for traditional pharmaceutical and biopharmaceutical clinical trials supply. He described how tissue stem cell counting technologies represented advantages both for discovery of novel drugs and for toxicology evaluations of new drug candidates. A major value presented was the opportunity for drug companies to realize hundreds of millions of dollars in reduced costs each year by using tissue stem cell counting tests for earlier identification of drugs that would fail late in clinical trials because of inducing chronic failure of organs and tissues like the liver and bone marrow. Currently applied animal toxicology studies miss many drugs with this disastrous character. Sherley described how such drugs could be detected in inexpensive cell culture tests by counting how stem cell-specific number and viability changed in their presence.

Though not a main focus of the presentation, Sherley ended his presentation with acknowledgement of Asymmetrexs recent introduction of the first-in-kind technology for counting therapeutic tissue stem cells and determining their dosage. The company holds issued patents for the technology and its use for drug evaluations in both the U.S. and U.K. In August of this year, it published a peer-reviewed report, co-authored with its partner AlphaSTAR Corporation, that describes the new method and its applications for stem cell therapy and drug evaluations. In September, the company was awarded a research and development grant from the National Institutes of Health-National Heart, Lung, and Blood Institute for continued development of the technology and its commercialization. These plans for the companys AlphaSTEM Test tissue stem cell counting technology were recently reported.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the AlphaSTEM Test) for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

See original here:
Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials - PR Web

Smith’s 2005 stem cell law to be reauthorized by House – InsiderNJ

Smiths 2005 stem cell law to be reauthorized by House

Rep. Chris Smith (R-NJ)statement submitted during debate in the House of Representatives

on the Stem Cell Therapeutic and Research ActSeptember 29, 2020

Margaret Hahnmy mother-in-lawpassed away on Friday and a Mass of Christian burial will be held today at St. Mary Church in South Amboy, New Jersey. She was 96 and was deeply loved and will be deeply missed.

MargaretPegwas a great womanwife, mother, grandmother, and great-grandmother. She selflessly devoted her life to public service including her amazing work as Sayreville Borough Clerk for twenty years. She had an incredible reputation for getting things done for the people. No matter who served as mayor or on Council, everyone knew she was the power.

My wife Marie and I will join family and friends today at her funeral and internment making it impossible for me to speak today during the debate on the reauthorization of a law I originally authored fifteen years agothe Stem Cell Therapeutic and Research Act of 2005and the Stem Cell Therapeutic and Research Act of 2015.

So, I submit these comments for the Congressional Record.

Madam Speaker, today the House of Representatives will vote to reauthorize the Stem Cell Therapeutic and Research Act.

This was an original idea of mine 20 years ago. Joined by 70 cosponsors, I introduced it in 2001 and again in 2003.

After five long years of hard work and numerous setbacks, my bill was finally enacted into law in 2005.

Beginning in 2001, Dr. Joanne Kurtzberg, who is President of the Cord Blood Association, helped draft my original law.Dr. Kurtzberg has said, Cord blood transplantation is now an established field with enormous potential. In the future, it may emerge as a source of cells for cellular therapies focused on tissue repair and regeneration.

The new law created a nationwide umbilical cord blood stem cell program, designed to collect, derive, type, and freeze cord blood units for transplantation into patients to mitigate and to even cure serious disease. Pursuant to the law, it also provided stem cells for research. The new cord blood program was combined in our 2005 law with an expanded bone marrow initiative, which was crafted over several years by our distinguished colleague, CongressmanBill Young.

I was the prime sponsor again when it was reauthorized in 2015.

Umbilical cord blood stem cells, obtained after the birth of a child, have proved highly efficacious in treating 70 diseases, including sickle-cell disease, lymphoma, and leukemia. And scientists are continuing to study and better understand the regenerative effects of cord blood cell therapies for other diseases and conditions. Bone marrow donations provide lifesaving transplants to treat diseases like blood cancer, sickle cell anemia, or inherited metabolic or immune system disorders.

The National Cord Blood Inventory (NCBI) provides funding to public cord blood banks participating in the program to allow them to expand the national inventory of cord blood units available for transplant. These units are then listed on the registry by the Be the Match Program. The funds appropriated thus far have led to an important increase in the overall number of high-quality cord blood units available through the national registry, including 150,000 NCBI units. Within the Be the Match registry, there are more than 783,000 NCBI units worldwide.

The Program registry allows patients and physicians to locate matching cord blood units, as well as adult donors for marrow and peripheral blood stem cells, when a family donor is not available. The Program is the worlds largest, most diverse donor registry, with more than 22 million volunteers and more than 300,000 public cord blood units. To date, the National Marrow Donor Program/Be The Match (NMDP), through its operation of the Program, has facilitated more than 100,000 transplants. More than 45,000 patients have receivedcord bloodtransplants, according Dr. Joanne Kurtzberg.

The reauthorization before us authorizes $23 million to be appropriated for fiscal year 2021 through fiscal year 2025. It also authorizes $30 million to be appropriated for fiscal years 2021 through 2025 for the bone marrow transplant program. This continues funding at the same levels authorized in the 2015 authorization bill.

Madam Speaker, each year nearly 4 million babies are born in America. In the past, virtually every placenta and umbilical cord was tossed as medical waste. Today, doctors have turned this medical waste into medical miracles.

Not only has God in His wisdom and goodness created a placenta and umbilical cord to nurture and protect the precious life of an unborn child, but now we know that another gift awaits us immediately after birth. Something very special is left behindcord blood that is teeming with lifesaving stem cells. Indeed, it remains one of the best kept secrets in America that umbilical cord blood stem cells and adult stem cells in general are curing people of a myriad of terrible conditions and diseasesover 70 diseases in adults as well as in children.

The legislation that is before us will enable even more patients to receive the treatments that they so desperately need.

(Visited 80 times, 4 visits today)

View post:
Smith's 2005 stem cell law to be reauthorized by House - InsiderNJ

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market -Key Players, Size, Growth, Incredible Potential, and Stagnant Progress According to New…

The global platelet rich plasma & stem cell alopecia treatment market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on treatment, indication, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides presence of key players working in the development of stem cell and platelet rich pharmaceutical products, thereby presenting a thorough analysis of the overall competitive scenario in the global platelet rich plasma & stem cell alopecia treatment market.

This report analyzes the current and future scenario of the global platelet rich plasma & stem cell alopecia treatment market for the period 2018 to 2026. Rise in awareness about platelet rich plasma therapies and stem cell therapies, increase in funding for alopecia treatment research and stem cell research, and increase in the incidence of autoimmune hair loss disorders are likely to be major drivers of the global platelet rich plasma & stem cell alopecia treatment market during the forecast period.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55800

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market Witness Most Promising Rise in Demand

The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Factors such as increase in demand for accurate and prompt treatment of alopecia and advancements in platelet rich plasma and stem cell therapies that have revolutionized the diagnostic science are likely to boost the market. Moreover, a rise in awareness about platelet rich plasma therapies and stem cell therapies is expected to drive the global market during the forecast period.

Increased awareness has driven demand for platelet rich plasma therapy & stem cell therapy in the past few years in countries such as Japan, India, Brazil, and Russia and developed regions such as North America and Europe. Additionally, private players are actively promoting the advantages of treatment of alopecia with stem cell therapy across the globe. A rise in the incidence rates of autoimmune hair loss disorders such as alopecia is estimated to boost the platelet rich plasma & stem cell alopecia treatment market. According to the Journal of Clinical, Cosmetic, and Investigational Dermatology, 2015, the lifetime incidence rate of alopecia areata is approximately 2% worldwide. This is expected to propel the market. However, a lack of treatment approval and high cost of alopecia treatment are likely to hinder the growth of platelet rich plasma & stem cell alopecia treatment market.

Request for Analysis of COVID19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55800

Based on treatment, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into platelet rich plasma therapy and stem cell therapy. The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. In terms of indication, the global platelet rich plasma & stem cell alopecia treatment market has been classified into androgenic alopecia, congenital alopecia, cicatricial or scarring alopecia and others. Based on end-user, the global platelet rich plasma & stem cell alopecia treatment market has been divided into hospitals, dermatology clinics, and others. The market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Key Players of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report:

Major players operating in the global platelet rich plasma & stem cell alopecia treatment market include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Key players are focused on research & development of alopecia treatment by investing in platelet rich plasma & stem cell alopecia therapies. Mergers & acquisitions, collaborations, and partnerships are helping companies expand their footprint and further develop effective treatments for alopecia.

Buy Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=55800&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read this article:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market -Key Players, Size, Growth, Incredible Potential, and Stagnant Progress According to New...

Risk Based Therapy Approach for Sickle Cell Anemia Patients is Ideal Scenario – MD Magazine

Although the therapeutic options for sickle cell anemia have expanded over the past years, the clinical complications of the condition as well as the limitations of these pharmacotherapies have called for an urgent need to implement a personalized treatment strategy for patients that is based on risk stratification.

In a recent article, Emily Meier, MD, of the Indiana Hemophilia and Thrombosis Center, elucidated on the key considerations in the prescribing of such therapies as well as the current barriers that preclude healthcare providers from achieving an optimal treatment strategy for these patients.

With increasing therapeutic options, the ideal scenario for children with SCA would be one similar to childhood acute lymphoblastic leukemia (ALL) risk stratification: treatment intensity varies with risk level, Meier wrote.

Thus, children who are at low risk for sickle cell anemia complications would receive less intense therapies, which includes a continuation of hydroxyurea. On the other hand, those with the highest risk would be recommended to immediately receive one or more curative therapies, such as hematopoietic stem cell transplant, gene therapy, transfusion therapy, voxelotor, and/or crizanlizumab.

Of course, as Meier noted, there are certain limitations that must be considered before implementing such a strategy.

For one, crizanlizumab and voxelotor are approved for ages 16 and 12 years, respectively. According to the risk based therapy model, high-risk patients should only use both therapies once age appropriate.

Similarly, patients with medium risk of complications should only use L-glutamine once they reach the appropriate age of 5 years.

Additionally, there is no validated predictor for the overall severity of the disease prior to the onset of associated complications. Currently available predictors of a severe outcome is an abnormal velocity on transcranial Doppler ultrasonography. These predictors identity children at highest risk for stroke.

Meier noted that there are no predictors for vaso-occlusive episodes or acute chest syndrome.

Furthermore, there is no unanimous agreement of what constitutes severe sickle cell anemia. However, the inclusion criteria for hematopoietic stem cell transplant is considered a promising start.

Overall, Meier suggested that hydroxyurea should be the standard of care in pediatric and adult patients, regardless of disease severity.

In adults with sickle cell anemia, a risk-based strategy should still be utilized, but the end organ injury makes such an approach more challenging to implement.

She suggested that the additional FDA-approved treatments should be based on clinical and laboratory complications that are still present even after hydroxyurea dosing has been maximized.

According to the seminal trials in support of these agents, L-glutamine and crizanlizumab should be considered as additional therapy in patients who continue to experience vaso-occlusive episodes. Meier also encouraged the addition of voxelotor to hydroxyurea for those adults who continue to have significant anemia.

Hopefully, as the number of SCA modifying and curative therapies increase, more innovative treatment strategies will be tested and lead to improved quality of life and increased life expectancy for individuals with SCA, she concluded.

The opinion piece, What are the key considerations when prescribing pharmacotherapy for sickle cell anemia? was published online at Taylor & Francis Online.

Read the rest here:
Risk Based Therapy Approach for Sickle Cell Anemia Patients is Ideal Scenario - MD Magazine

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2025 – The…

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market report 2020 gives a complete detail of key drivers, leading market players, key segments, and regions. Besides this, the experts have extremely studied diverse geological areas and presented a competitive scenario to assist new entrants, leading market players, and investors to determine emerging economies. These insights offered in the Platelet Rich Plasma and Stem Cell Alopecia Treatment report would benefit market players to plan strategies for the outlook and gain a well-built position in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market growth.

The study of Platelet Rich Plasma and Stem Cell Alopecia Treatment market highlights important aspects such drivers, challenges, restraints, and expansion prospects prevailing in this particular industry sphere.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/11036

As per the report, Platelet Rich Plasma and Stem Cell Alopecia Treatment market is projected to grow substantially with XX% CAGR over 2020-2025, which is poised to amass momentous returns by the end of analysis timeframe.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/11036

The nation-wide lockdown, travel bans, and movement restrictions, in every part of the world, to curb COVID-19 spread, are believed to have doomed many industries. Consequently, all companies are revising their finances and business strategies to incorporate the set-up over the forthcoming period. With our thorough analysis of this marketplace, we offer recommendations to frame robust contingency plans in order to nullify business uncertainties.

The report further entails a comprehensive scrutinization of various segmentations, enabling the reader to understand the overall impact on market dynamics.

Major highlights of Platelet Rich Plasma and Stem Cell Alopecia Treatment market report:

List on segments in Platelet Rich Plasma and Stem Cell Alopecia Treatment market report:

Geographical landscape: North America, Europe, Asia-Pacific, South America and Middle East & Africa

Product terrain: Androgenic Alopecia, Congenital Alopecia and Cicatricial Or Scarring Alopecia

Application scope: Hospital, Dermatology Clinic and Other

Competitive hierarchy: Kerastem, Stemcell Technologies, Eclipse, Glofinn Oy., Regen Lab SA, Histogen and RepliCel Life Sciences

Key questions answered in the report:

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/11036

View original post here:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2025 - The...

Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October…

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020.

The Jefferies Cell Therapy Virtual Summit will take place on October 5-6, 2020. Cytovia CEO Dr. Daniel Teper will present on October 6th at 5.30 PM EDT. Webcast link

The BIO Investor Forum will take place on October 13-15, 2020. Cytovia will have an on-demand company presentation during the Bio Investor Forum Digital.

The New York Stem Cell Foundation Conference will take place on October 20-21, 2020. Dr. Wei Li, Cytovia Executive Vice President, R&D and Chief Scientific Officer, will present during the Stem Cell Application in Therapeutics session, on October 21st at 11.15 AM EDT.

The webcast links will be available on the company website and social media pages.

On-demand interview opportunities with Cytovia Therapeutics spokespersons: Daniel Teper, CEO Wei Li, Chief Scientific Officer

ABOUT CYTOVIA THERAPEUTICS: Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com and Follow Cytovia on Social Media Facebook, LinkedIn, Twitter.

For more information please contact: Cytovia Therapeutics, Inc Sophie Badr, Vice President, Corporate Affairs 1 (929) 317 1565 sophie.badre@cytoviatx.com

Read more:
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October...

Timothy Ray Brown, First Person to Be Cured of HIV, Dies – The Scientist

Timothy Ray Brown, who became the first HIV patient to be cured of the infection, died September 29 of leukemiathe very disease that led to the fortuitous eradication of the virus from his body. He was 54.

Until he disclosed his identity, Brown was known as the Berlin patient, whose HIV infection was eliminated in 2007 after undergoing a stem cell transplant to treat acute myeloid leukemia. The bone marrow donor was selected to have a naturally occurring genetic variant that blocked HIV from entering cells. The treatment workedboth for his cancer, and his viral infection.

Timothy symbolized that it is possible, under special circumstances to cure HIV, Gero Htter, the doctor who performed the stem cell transplant, tells theAssociated Press.

Until2016, Brown remained the only person in the world to have been cured of AIDS using this approach and his unique experience motivated him to advocate for AIDS research. As he toldThe Scientist in 2015, I didnt want to be the only one in my club.

Brown was born in 1966 and grew up in Seattle. He was living in Berlin when he received the diagnosis of leukemia and sought treatment from Htter. The doctor had previously read about individuals with variants in the CCR5 gene, which codes for a receptor on cell surfaces, that gives themnatural immunity to HIV. Upon finding out that Brown was HIV-positive, Htter decided to look for a bone marrow donor who might have this variant. As Htter explained to The Scientist in 2015, he screened dozens of donors until he found one with the so-called delta32 mutation.

Within months of the transplant, the virus was gone from Browns cells, although his recovery was difficult and he required a second transplant to treat the leukemia.

In 2012, Brown and activist Dave Purdy started the Cure for AIDS Coalition to raise awareness of HIV research. According to aFacebook post by Browns partner, Tim Hoeffgen, Tim committed his lifes work to telling his story about his HIV cure and became an ambassador of hope. Tim also gave numerous blood and tissue samples to researchers after his cure.

The invasiveness of the bone marrow transplant precludes it from being applied more widely to HIV patients, but the insights gained from Browns successful cure have inspired further work on CCR5. For instance, in 2017, researchers used CRISPR to disrupt the gene in human hematopoietic stem cells anddemonstrated that these cells could ward off HIV infection in mice transplanted with them. More recently, andcontroversially, the gene was a target of CRISPR-based editing in human embryos to make them resistant to HIV.

Brown never again tested positive for HIV. His leukemia, however, relapsed five months ago.

Timothy was a champion and advocate for keeping an HIV cure on the political and scientific agenda, Sharon Lewin, the director of the Doherty Institute in Melbourne, Australia, tells theBBC. It is the hope of the scientific community that one day we can honour his legacy with a safe, cost-effective and widely accessible strategy to achieve HIV remission and cure using gene editing or techniques that boost immune control.

Read more here:
Timothy Ray Brown, First Person to Be Cured of HIV, Dies - The Scientist

Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering…

DUBLIN, Sept. 30, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

In Global Regenerative Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking 2.1. Introduction 2.2. Regenerative Medicine partnering over the years 2.3. Most active Regenerative Medicine dealmakers 2.4. Regenerative Medicine partnering by deal type 2.5. Regenerative Medicine partnering by therapy area 2.6. Deal terms for Regenerative Medicine partnering 2.6.1 Regenerative Medicine partnering headline values 2.6.2 Regenerative Medicine deal upfront payments7 2.6.3 Regenerative Medicine deal milestone payments 2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals 3.1. Introduction 3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers 4.1. Introduction 4.2. Most active Regenerative Medicine dealmakers 4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory 5.1. Introduction 5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking

Appendices Appendix 1 - Regenerative Medicine deals by company A-Z Appendix 2 - Regenerative Medicine deals by stage of development Appendix 3 - Regenerative Medicine deals by deal type Appendix 4 - Regenerative Medicine deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/dcq9uu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Excerpt from:
Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering...

UM171 saves another life – Newswise

Newswise In a world first, a young man suffering from severe aplastic anemia who could not be helped by standard treatments has been given a life-saving blood transplant with the made-in-Canada UM171 molecule.

The procedure was done by a medical team at the Institute of Hemato-oncology and Cellular Therapy (iHOTC) of Maisonneuve-Rosemont Hospital and the Institute for Research in Immunology and Cancer, both affiliated with Universit de Montral.

The young mans case history, including the lifesaving transplant, was recently published in the scientific journal European Journal of Haematology, highlighting the unique and revolutionary properties of the UM171 molecule.

An autoimmune disease, severe aplastic anemia destroys stem cells in bone marrow and leads to a halt in the production of red blood cells, white blood cells and platelets. For allografting (grafting between individuals) for this disease, the donor's stem cells must be as compatible as possible with those of the recipient to avoid the risk of immunological complications.

No donor option

If no compatible family or unrelated donor can be found, stem cells from a semi-identical family donor, also known as a haplo-identical donor, may be considered, under certain conditions, as an alternative source of cells. However, a family member must be healthy and available for such a procedure; the young man in this case did not have that option.

Cord blood transplantation, which is less demanding in terms of compatibility, is a good option for many patients requiring a stem cell transplant. On the other hand, cord blood generally does not contain enough stem cells for an adult patient weighing more than 70 kg; it produces a slow rise in white blood cells with an increased risk of often fatal infections.

In addition, the rate of graft rejection the destruction of infused cord cells by the recipient's immune system is very high in patients with severe aplastic anemia who have received multiple blood transfusions.

It was after having exhausted all our treatment options that UM171, which had already proven itself in a clinical trial in blood cancer patients, came into play, said UdeM medical professor Jean Roy, a hematologist and clinical researcher at the MRH.

35-fold increase

As well as increasing the number of stem cells in a unit of umbilical cord blood by an average of 35 times, it greatly reduces the risk of a frequent long-term immunological complication (graft-versus-host disease) requiring years of use of toxic immunosuppressive drugs.

The researchers success confirms the excellent performance of UM171, which has already been demonstrated in two other studies conducted by iHOTC research teams with very encouraging results. A third study is now underway.

This young man's story and the other studies with UM171 clearly demonstrate how innovative clinical research, set up by local investigators, can create a culture of excellence and improve care to save more lives, said IHOTC director Denis Claude Roy.

The future will certainly bring us more such accomplishments, and thats very encouraging.

Maisonneuve-Rosemont Hospital is one of 26 institutions that are part of the Centre intgr universitaire de sant et de services sociaux de l'Est-de-l'le-de-Montral, serving over half a million Montrealers.

Link:
UM171 saves another life - Newswise

Cell Therapy Processing Market COVID 19 Status, Growth Rate by Applications, and Future Forecast 2026 – The Daily Chronicle

The global Cell Therapy Processing market is segregated on the basis of Process as Cell Processing, Cell Preservation, Distribution, and Handling, and Process Monitoring and Quality Control. Based on Product Type the global Cell Therapy Processing market is segmented in Equipment, 1 Cell Processing Equipment, 2 Single-Use Equipment, 3 Other Equipment, Systems & Software, and Consumables. Based on End User the global Cell Therapy Processing market is segmented in Life Science Research Companies and Research Institutes.

Browse Full Report: https://www.marketresearchengine.com/cell-therapy-processing-market

The global Cell Therapy Processing market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Cell Therapy Processing market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Cell therapy is the therapeutic application of cells despite cell kind or clinical indication a platform technology. Regenerative drugs is an approach to treating patients and so definitely not a platform technology. Its nearest to a hospital specialty, for example, medicine, medical specialty or palliative drugs, in alternative words platform technology independent. Its goals are ultimately to cure and so a paradigm shift away from typical symptom management and pain management. While its true that some cell therapies are regenerative, the bulk are not. Even as regenerative drugs is much larger than regenerative cell therapies alone, cell therapies collectively represent a market opportunity several orders of magnitude bigger than regenerative drugs. Equating one with the other is therefore not advantageous however instead will each a major disservice.

The global Cell Therapy Processing market is expected to exceed more than US$ 11.5 Billion by 2024, at a CAGR of 16.2% in the given forecast period.

Market Insights

Based on Cell Type, the global Cell Therapy Processing market is segmented in Human Cells, 1 Stem Cells, 2 Differentiated Cells, and Animal Cells.

Competitive Rivalry

Stemcell Technologies, Miltenyi Biotec GmbH, Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius, Merck KGaA, Lonza Group, Thermo Fisher Scientific, Inc., Terumo Bct, Inc, and others are among the major players in the global Cell Therapy Processing market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Cell Therapy Processing Market has been segmented as below:

The Cell Therapy Processing Market is segmented on the lines of Cell Therapy Processing Market, By Process, Cell Therapy Processing Market, By Product Type, Cell Therapy Processing Market, By End User, Cell Therapy Processing Market, By Cell Type, Cell Therapy Processing Market, By Region and Cell Therapy Processing Market, By Company.

Cell Therapy Processing Market, By Process this market is segmented on the basis of Cell Processing, Cell Preservation, Distribution, and Handling and Process Monitoring and Quality Control. Cell Therapy Processing Market, By Product Type this market is segmented on the basis of Equipment its covers 1 Cell Processing Equipment, 2 Single-Use Equipment & 3 Other Equipment. Systems & Software and Consumables. Cell Therapy Processing Market, By End User this market is segmented on the basis of Life Science Research Companies and Research Institutes. Cell Therapy Processing Market, By Cell Type this market is segmented on the basis of Human Cells its covers 1 Stem Cells & 2 Differentiated Cells. And Animal Cells. Cell Therapy Processing Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Cell Therapy Processing Market, By Company this market is segmented on the basis of Stem cell Technologies, Miltenyi Biotec GmbH, Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius, Merck KGaA, Lonza Group, Thermo Fisher Scientific, Inc. and Terumo Bct, Inc.

The report covers:

Report Scope:

The global Cell Therapy Processing market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Cell Therapy Processing market share. Major industry players with significant revenue share include Stem cell Technologies, Miltenyi Biotec GmbH , Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius , Merck KGaA, , Lonza Group , Thermo Fisher Scientific, Inc., Terumo Bct, Inc, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/cell-therapy-processing-market

Table of Contents:

5. Cell Therapy Processing Market, By Process

Other Related Market Research Reports:

Cell-based Assays Market 2019| Set for Rapid Growth During by 2024 MRE Report

Center Pivot Irrigation Systems Market 2019: Industry Demand, Size, Growth Report By 2024 Market Research Engine

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read the original here:
Cell Therapy Processing Market COVID 19 Status, Growth Rate by Applications, and Future Forecast 2026 - The Daily Chronicle